What do biotech investors look for when considering a deal? Strong leadership, strategic foresight, financial efficiency, and deep industry knowledge are all key deciding factors. Curious to learn more? Gain invaluable insights on M&A advisory and investor decision-making from Bracken Managing Partner, James Gilligan, in this blog post: https://lnkd.in/eMzHrtpx #LifeSci #Biopharma #Investing #DueDiligence #Bracken
Bracken’s Post
More Relevant Posts
-
A crucial path towards meeting revenue goals and seeing marketable results is attracting the right investors, especially in the life science industry. Strong management, successful strategic plans, and key experience in the field have a common dividend: they're vital deciding factors for biotech investors. Interested in learning more? We've got that covered. Read the inside scoop with Bracken's Managing Partner Jim Gilligan here: https://lnkd.in/eHs8Kaxj #Biopharma #Investing #DueDiligence #Bracken
Biotech Investors: Who They Are & What They Want
thebrackengroup.com
-
Seeking to help biotechnology, pharmaceutical and medical device companies advance their life-impacting ideas.
A crucial path towards meeting revenue goals and seeing marketable results is attracting the right investors, especially in the life science industry. Strong management, successful strategic plans, and key experience in the field have a common dividend: they're vital deciding factors for biotech investors. Interested in learning more? We've got that covered. Read the inside scoop with Bracken's Managing Partner Jim Gilligan here: https://lnkd.in/gFUNi67K #Biopharma #Investing #DueDiligence #Bracken
Biotech Investors: Who They Are & What They Want
thebrackengroup.com
-
A crucial path towards meeting revenue goals and seeing marketable results is attracting the right investors, especially in the life science industry. Strong management, successful strategic plans, and key experience in the field have a common dividend: they're vital deciding factors for biotech investors. Interested in learning more? We've got that covered. Read the inside scoop with Bracken's Managing Partner Jim Gilligan here: https://lnkd.in/gqyTg-TV #Biopharma #Investing #DueDiligence #Bracken
Biotech Investors: Who They Are & What They Want
thebrackengroup.com
-
WSB Investor Call | June 21, 2022 (Preview) Here's a preview of the investor call with David Maris and Sarepta Therapeutics CEO Douglas S. Ingram. Whether you own $SRPT or thinking of getting long, you can't miss this discussion. "Our goal here is to delve deeper into the implications of the approval and understand Sarepta's longer term objectives." - David Maris "This is an enormous moment for the company." - Doug Ingram Access the entire Investor Call on $SRPT and don't miss Doug's incredible insights near the end on the importance of corporate culture in his organizations. Click the link in the comments sections to access. Fantastic discussion gentlemen! #InvestSmarter
-
Thoughts on this? >> TPG reveals $580M life sciences fund, which has already backed multiple biotechs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #biotech #pharmaceutical #healthcare
TPG reveals $580M life sciences fund, which has already backed multiple biotechs
endpts.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> TPG reveals $580M life sciences fund, which has already backed multiple biotechs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharmaceutical #pharma #biotech
TPG reveals $580M life sciences fund, which has already backed multiple biotechs
endpts.com
-
R&D, Drug Development & Medical Affairs, Market Access Global Clinical Studies and Product Lifecycle Management, RA, Board of Directors, International Speaker, Development Programs, Strategic Leadership.
Not easy to start a new company
“We had no money, we had no business plan.” Tim Van Hauwermeiren, CEO of argenx, reflects on how he and his co-founders beat the odds when they launched the biotech in 2008. https://mgstn.ly/3wRCHS7
-
In the latest episode of Exceptional Leaders / Exceptional Ideas, our CEO Tim Van Hauwermeiren discusses his entrepreneurial journey, navigating the launch of argenx, and our approach to developing innovative treatments for autoimmune conditions. Watch the full episode below.
“We had no money, we had no business plan.” Tim Van Hauwermeiren, CEO of argenx, reflects on how he and his co-founders beat the odds when they launched the biotech in 2008. https://mgstn.ly/3wRCHS7
-
Inspiring Science, Inspiring Teamwork, Inspiring Entrepreneurship @argenx . See below for the full interview with our CEO Tim Vanhauwermeiren.
“We had no money, we had no business plan.” Tim Van Hauwermeiren, CEO of argenx, reflects on how he and his co-founders beat the odds when they launched the biotech in 2008. https://mgstn.ly/3wRCHS7
Seeking to help biotechnology, pharmaceutical and medical device companies advance their life-impacting ideas.
4moImportant considerations to keep in mind!